Paradigm Coaching

@Anthony__VR @tom_the_bomb__ My understanding is that the enrolment was always in the plan. You may be correct about recruitment, but that's not the main point. They'll already know if early doses had any issues, and I don't expect they would open the next site if so. That's my takeaway. Good initial signs.

@tom_the_bomb__ Asking a question(s) to avoid confirmation bias Was the enrollment question not always in the plan? Can we know? Could it be that current 2 sites are just not recruiting enough patients so the's need to expand? Meaning P1 not progressing quick enough?

A new site has been opened for the #AVCT AVA6103 trial. When you already have ~7 weeks of clinical data, expanding site activity is a VERY positive sign. For P1A, that’s what you’d expect if: 1. Activation timelines are progressing properly. 2. Enrolment is expanding. 3. They're prepping to move through escalation cohorts efficiently. A HUGE update just before the weekend 👌 clinicaltrials.gov/study/NCT07454…

@JStonker @STWpharma @downunderfutbol Great detective work again, Stonks. 💪🏼🙏🏼

@downunderfutbol Some minor updates to AVA6000 today as well - estimated study completion 15th June #version-content-panel" target="_blank" rel="nofollow noopener">clinicaltrials.gov/study/NCT04969… #AVCT

Michigan open for recruitment #avct

@royaldaring Next few days max, I think. 'As soon as it has been edited', they said. Keen to see it myself.

Do we know when the Science Day recording will be released? #avct

@tom_the_bomb__ @PJ_Crabb Still need to square the added indications and the small £10m raise almost simultaneously. Unless she's done another Big Al and thought a deal was in the bag (which led to the emergency raise), they must be very confident of more funding coming from somewhere very shortly.

@PJ_Crabb I agree that a deal on 6000 changes everything. Trinity anticipated this in H1 (not long left). Get $XXXM upfront across all indications (or $XX across one indication) and this completely rerates. I'd still be keen to then see a dual listing to go up a level again.

NASDAQ listing back on the agenda for some and $30m raise touted. Surely CLNs need clearing first so $60m more likely. Makes sense to sell 6000, strengthened balance sheet for 6103 initial data and extend runway another 12 months. 6103 initial data could well lead to TO. #AVCT

@tom_the_bomb__ @Andrewp37075755 @avacta Yes, this ☝🏼. Looks to me like they're showing that the platform works as expected. Which changes the narrative from 'That looks like an interesting asset to acquire' (AVA6000 only) to 'That platform is a whole new modality, which we can't let our rivals take away from us.' #AVCT

@Andrewp37075755 @avacta Many single asset co's sell for $1B-$3B. If your tech is outperforming the most successful ADCs, the strategy is to prove up as much IP as poss, as quickly as poss, before the inevitable BP fight. We're +3% over the last 6 months. The market wants a deal. BoD focused on leverage.

There's Daiichi again. Before any major pharma deals, their teams have to answer the question: "does this tech work better than what we already have?" That process is very slow. #AVCT is running diligence for them, using their own drugs as the benchmark. Very clever @avacta

@ScottLilley19 @tom_the_bomb__ @JStonker Well, we'll see. Not claiming I'm an oracle - just piecing together the information I have, given that this is billed as more than just a Science Day this time - 'next chapter', etc.

@ParadigmCoachi1 @tom_the_bomb__ @JStonker It’s a science day not sure what people are expecting lmao! #AVCT

CC Oct '25: Dual payload tech is true leapfrog with a no. of advantages over ADCs. A no. of catalysts coming up in next few months to a year. CC Jan '26: "I’m giving it about 6 months for us to figure out exactly what are those first few combos we’re gonna take forward.” #AVCT

@tom_the_bomb__ @Timj65 Dunno, but that's what all the behaviour and recent announcements point to. Small raise, removal of lifetime dose limit (so they've had a Type C mtg with FDA), extra indications. Put them together, and they're the updates that make sense. 🤷🏻‍♂️🤞🏼 #AVCT

@ParadigmCoachi1 @Timj65 6000 data, Accelerated approval & advanced licensing discussions - the science day hat trick? There was me being happy with an update on the pipeline 😁 #GoBigOrGoHome

+2.01% on the day. +1.67% on the week. The market isn’t pricing in anything material tomorrow. If it’s wrong, we gap up. #AVCT

@tom_the_bomb__ @JStonker I think they HAVE to address funding/licensing tomorrow. You don't expand the indications, while simultaneously only raising £10m, unless you're VERY confident there's more cash on the way. For AA AND partnerships, expanding indications makes sense... 🤞🏼🚀 #AVCT

@JStonker Importantly, they'll need to demonstrate how they take the first few combos forward.

@RAH00084 Totally, RAH. • AVA6000 (anthracycline → weak TI) • AVA6103 (irinotecan/SN‑38 → fallen angel) • AVA6207 (DXd → liberated ADC payload) Three different drugs. Three different toxicity profiles. Three different mechanisms. One platform fixing all of them. 💰💰💰💰

This is where the enormous $$$$ is. Ironically the market gets most excited about #AVCT events which drive the least value. Sustain release? Great, here’s +5%. Dealing on any asset which represents 1/50 of preCISION’s value utility? Yippee 300%+. Prove Gen2. Simple. HODL.

Or those which have failed due to safety and/or efficacy issues. #AVCT reviving those fallen angels.

@Jenkoool Since we're playing... - AVA6000 still showing strong data (stable disease and PRs) - announcement of AA for AVA6000, hence BOIN P2 and added indications - advanced licensing/partnership discussions (but not full announcement) - AVA6103 too early, but progressing as expected

Have a feeling it’s going to be a good week #avct but realistically I’m not expecting commercial news. I suspect we get some form of SGC update and a hint towards 6103 initial safety. We’re all expecting news after CC’s tweet. But what news? (Comment any other ideas)

@drewster_1965 @Paulbritland1 @tom_the_bomb__ BP - I think this is simply a value/data mismatch. #AVCT know what they're sat on. It'll come when BP can justify what Avacta want. II - three letters. AIM. Puts Avacta off the table for many due to risk profile of AIM. When data/LD comes and there's a steady cash flow... 🚀

@Paulbritland1 @tom_the_bomb__ "They can't" yet somehow they continue to do so. Companies with supposedly inferior science, earlier umin the business life cycle, are attracting BP bids for multiples of #avct Mkt Cap. Why? What reasons are there other than BP simply aren't excited by Avacta? (ditto IIs)

Today, AbbVie agreed up to $1.45B to fund a phase 1 asset that started dosing today. What deal value could #AVCT achieve for a phase 2-ready asset with 4.5+ years of clinical data & (potentially) an accelerated approval pathway?

@tom_the_bomb__ @ripley124 @jivetur88775834 There is also the 'minority' play (IMHO, maybe 10% chance). BP see they can't afford total exclusivity, and make sweet JV deals with Avacta to ensure they keep exclusivity of their own drugs, and #AVCT end up a very wealthy and lean independent company.

@ripley124 @jivetur88775834 @ParadigmCoachi1 BP play risk vs price (not just price). If 6103 works, the risk drops but so does their negotiating power. Then it becomes about competition. Multiple bidders, or losing access to a platform that could transform their pipeline. That’s when we could see aggressive multiples.

Increasingly convinced that #AVCT T/O comes soon. CC 'won't start P2 w/o a partner' - a veiled power play. 'We know how good it is - show us the money.' LD vs T/O - no BP wants to be left behind by an LD. This increases likelihood of T/O. Strategy mtgs must be well underway.

@jivetur88775834 @ripley124 There's undoubtedly a ceiling on what can be offered in event of TO. There are only 2 or max 3 bidders who seem able to stomach a £40bn+ bid. Where, when/if the platform is proven, they could, on paper, be worth more. That's where it'll be interesting to see how it plays out.

@ripley124 @ParadigmCoachi1 That's one way to look at it. I'm sure offers have been made. BP will offer low (i.e., include risk factors) and Avacta will be asking high. When these two meet (typically after MoA is confirmed/refuted) then a deal is done.

@DrHelenFry He really was a hero. Another one who was mentioned extensively in the Between Silk & Cyanide book, and I also enjoyed The White Rabbit too. His cabinet in the IWM is like a shrine for me.

Forest Frederick Edward Yeo-Thomas was known as "Tommy" to his comrades, and the "White Rabbit" to the Gestapo. His legendary elusiveness made him one of the most hunted men in occupied Europe. A driving force behind the Pat O’Leary escape line, he helped hundreds of Allied airmen evade capture and return home. He was a hero and we should continue to remember his wartime work.

@law70437 @Timj65 Sorry to hear that, SJL - I lost a very good friend to cervical cancer aged 34 a few years ago too. Heartbreaking to see her two wee boys left behind. Really hoping that #AVCT brings some ability to significantly improve survival rates too.

Back here now after some months away watching mum suffer from - and ultimately succumb to - mesothelioma. A FAP-high cancer that I hope, one day, Avacta might tame with its pre|CISION platform. My faith in CC and the #avct team is unabated. Exciting newsflow just up ahead.

@Livinginthesurf @jivetur88775834 Might come back to @BobDibble8 's point - Avacta might have certain suitors they want to work with, or not.

@Livinginthesurf @jivetur88775834 Oh, I know some companies will be seeing privileged data, but the point is it might not be all of them, if Avacta choose not to share. Would seem a bit odd to exclude any suitors from our perspective, but it's their prerogative!

@Livinginthesurf @jivetur88775834 As Cumulus pointed out earlier - they MAY already be seeing the data...

@jivetur88775834 @ParadigmCoachi1 They will already be seeing the data. Thats the catch.

@Mike182035 @Ruthyrururu @jivetur88775834 Indeed, Mike - we're all just guessing! But you do make a good point. T/O not only option. It's the only option if one company has the firepower to buy outright. But possibly sweet JV/LD deals with exclusivity is a way for #AVCT to stay independent AND give BP what they want.

@ParadigmCoachi1 @Ruthyrururu @jivetur88775834 #AVCT Hypothetically I do concede that AZ's position is interesting as ideally they need to find a way of preventing Lilly winning the auction for 6103 partnering It's all good fun discussing, but there are so many permutations, and we'll know soon enough GLA 3/3